Bleeding and antiplatelet therapies: a combined pharmacovigilance analysis of FDA adverse event reporting system database and Japanese adverse drug event report database, and the role of pharmacists

Background: Antiplatelet agents are critical for preventing cardiovascular events. However, these therapies are associated with potentially fatal bleeding risks. This study aimed to comprehensively analyze bleeding events associated with antiplatelet therapies over the past two decades and investigate the role of pharmacist-led interventions in mitigating these risks. Methods: Data were extracted from the FDA Adverse Event Reporting System (FAERS) database and Japanese Adverse Drug Event Report (JADER) database, both spanning reports from 2004 to 2024. Signal detection was performed using four algorithms—Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayes Geometric Mean (EBGM). The analysis included temporal trends, indication distribution, time-to-onset, and outcomes of bleeding events. Additionally, the impact of combined drug use on bleeding risk was assessed. The impact of pharmacists in antiplatelet medication management was reviewed, focusing on interventions and their effectiveness in clinical settings. Results: A total of 22,546 bleeding event reports were identified in FAERS and 8,916 in JADER. The analysis revealed significant signals for various bleeding AEs, with the highest signal strength observed for rare events such as haemorrhagic thyroid cyst, spinal subarachnoid haemorrhage, and haemorrhagic adrenal infarction in FAERS, while the three highest signal strengths were Heyde’s Syndrome, habitual abortion, and thyroid haemorrhage in JADER. The analysis revealed that older adults aged 65 or older and patients requiring hospitalization were disproportionately affected. The combined use of antiplatelet drugs with NSAIDs, anticoagulants, and other drug classes significantly increased bleeding risk. The time-to-onset analysis showed that bleeding events could occur at any time during antiplatelet therapy, highlighting the need for continuous monitoring. Pharmacist-led interventions were reviewed and found to be effective in reducing bleeding complications and improving patient outcomes. Conclusion: This study provides robust evidence of the bleeding risks associated with antiplatelet therapies across diverse clinical settings, emphasizing the need for heightened clinical vigilance. Furthermore, it highlights the critical role of pharmacists in optimizing antiplatelet therapy management and reducing bleeding complications.